Nimotuzumab (another monoclonal antibody against EGFR) in combination with gemcitabine showed a significant improvement in OS compared to gemcitabine alone for metastatic PDAC, …

2024年10月21日 · In order to analyze the dynamics of potential prognostic biomarkers and further quantify their relationships with the overall survival (OS) of advanced PDAC patients, we …

2022年3月29日 · Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is most frequently detected at advanced stages, limiting treatment options to systemic...

在胰腺癌症的组织学亚型中，pdac（胰腺导管腺癌）是最常见的外分泌肿瘤，也是最常见的胰腺癌。pdac占胰腺癌的90%以上，与胰腺神经内分泌肿瘤（该器官第二常见的肿瘤）有着不同的分 …

Pancreatic ductal adenocarcinoma (PDAC) is currently the fourth leading cause of death in the United States and is expected to be ranked second in the next 10 years due to poor prognosis …

2025年3月20日 · Background Pancreatic ductal adenocarcinoma (PDAC) is difficult to detect early and highly aggressive, often leading to poor patient prognosis. Existing serum biomarkers like …

2024年11月21日 · Mutations in KRAS are associated with poorer overall survival (OS) compared with KRAS wild-type (WT) PDACs [4, 6]. The pathomechanism of many KRAS mutations …

2025年3月27日 · The prognosis of pancreatic ductal adenocarcinoma (PDAC) is poor 1, 2 and ranks among the leading causes of cancer mortality in the EU (3).Patients are frequently …

Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent pancreatic carcinoma, with an overall 5-year survival (OS) of 8% [1–3]. It is the fourth leading cause of cancer death, and is …

2021年4月6日 · The phase III Molecular Profiling-based Assignment of Cancer Therapy (MPACT) trial demonstrated that a combination of gemcitabine with nab-paclitaxel had a better OS than …